Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons - PubMed (original) (raw)
Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons
Bruce A Mungall et al. Virus Res. 2004 Jul.
Abstract
Neuraminidase (NA) inhibitors (NI) have recently been licensed for the prophylaxis and treatment of influenza virus infection in humans. This study has utilized a new chemiluminescent (CL) neuraminidase assay to routinely monitor more than a thousand influenza field isolates collected worldwide during the 2000-2002 seasons for susceptibility to both licensed NIs, zanamivir, and oseltamivir by determining the 50% inhibitory concentration (IC50). Our data demonstrated that influenza A viruses of the N2 subtype were less susceptible to zanamivir, but not oseltamivir, than those of the N1 subtype such that 41 of 45 confirmed H1N2 isolates could be reliably differentiated from H1N1 viruses based on their zanamivir susceptibility. Pre-titration of influenza A viruses appeared to have no effect on IC50 determined for either NI, while pre-titration of influenza B viruses significantly reduced oseltamivir IC50 and increased zanamivir IC50. Influenza B viruses were less susceptible to either compound than type A isolates. The CL assay is a rapid and reliable method for screening large numbers of influenza isolates for NI susceptibility. Reassortant viruses of the H1N2 subtype that started to circulate worldwide during the 2001-2002 season can be reliably separated from H1N1 viruses based on their zanamivir susceptibility, enabling large scale screening of H1 isolates for determining the prevalence of such reassortants.
Similar articles
- Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC, Barr IG, Hartel G, Hampson AW. Hurt AC, et al. Antiviral Res. 2004 Apr;62(1):37-45. doi: 10.1016/j.antiviral.2003.11.008. Antiviral Res. 2004. PMID: 15026200 - A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
Hurt AC, Barr IG, Komadina N, Hampson AW. Hurt AC, et al. Virus Res. 2004 Jul;103(1-2):79-83. doi: 10.1016/j.virusres.2004.02.017. Virus Res. 2004. PMID: 15163493 - Zanamivir. A potent and selective inhibitor of influenza A and B viruses.
Aoki FY, Hayden FG. Aoki FY, et al. Clin Pharmacokinet. 1999;36 Suppl 1:v-ix. Clin Pharmacokinet. 1999. PMID: 10429834 Review. No abstract available. - [Critical review of anti-influenza drugs].
van Loon FP, Voordouw AC, Simonian S, Koopmans PP. van Loon FP, et al. Ned Tijdschr Geneeskd. 2000 Jan 22;144(4):165-7. Ned Tijdschr Geneeskd. 2000. PMID: 10668542 Review. Dutch.
Cited by
- Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir.
Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Rameix-Welti MA, et al. PLoS Pathog. 2008 Jul 25;4(7):e1000103. doi: 10.1371/journal.ppat.1000103. PLoS Pathog. 2008. PMID: 18654625 Free PMC article. No abstract available. - Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method.
Deyde VM, Nguyen T, Bright RA, Balish A, Shu B, Lindstrom S, Klimov AI, Gubareva LV. Deyde VM, et al. Antimicrob Agents Chemother. 2009 Mar;53(3):1039-47. doi: 10.1128/AAC.01446-08. Epub 2009 Jan 5. Antimicrob Agents Chemother. 2009. PMID: 19124660 Free PMC article. - EGCG induces β-defensin 3 against influenza A virus H1N1 by the MAPK signaling pathway.
Mou Q, Jiang Y, Zhu L, Zhu Z, Ren T. Mou Q, et al. Exp Ther Med. 2020 Oct;20(4):3017-3024. doi: 10.3892/etm.2020.9047. Epub 2020 Jul 24. Exp Ther Med. 2020. PMID: 32855668 Free PMC article. - Human influenza surveillance: the demand to expand.
Layne SP. Layne SP. Emerg Infect Dis. 2006 Apr;12(4):562-8. doi: 10.3201/eid1204.051198. Emerg Infect Dis. 2006. PMID: 16704802 Free PMC article. - Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008.
Dijkstra F, Jonges M, van Beek R, Donker GA, Schellevis FG, Koopmans M, van der Sande MA, Osterhaus AD, Boucher CA, Rimmelzwaan GF, Meijer A. Dijkstra F, et al. Open Virol J. 2011;5:154-62. doi: 10.2174/1874357901105010154. Epub 2011 Dec 23. Open Virol J. 2011. PMID: 22253652 Free PMC article.